Natera Inc (NTRA)
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
IQVIA Holdings Inc. (IQV)
IQVIA Reports Third-Quarter 2025 Results
Lifecore Biomedical (LFCR)
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
Nutriband Inc. (NTRB)
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Alkermes plc (ALKS)
Alkermes plc Reports Third Quarter 2025 Financial Results
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Castle Biosciences Inc (CSTL)
Castle Biosciences to Participate in Upcoming Investor Conferences
Ocular Therapeutix Inc (OCUL)
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
Entrada Therapeutics Inc. (TRDA)
Entrada Therapeutics to Present at Upcoming Investor Conferences
Bioventus Inc (BVS)
Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025